rs17699436 — TBX21 TBX21 Downstream Regulatory Variant

Intergenic variant 5 kb downstream of TBX21 (encoding the T-bet transcription factor) within the TBX21/OSBPL7 intergenic region; the G allele is associated with systemic sclerosis susceptibility and is thought to tag regulatory variation affecting the TBX21-IFNG transcriptional axis governing Th1 immune polarization.

See your personal result for TBX21

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TBX21 Downstream Locus — Tuning the T-bet/IFN-gamma Immune Axis

Every naïve T cell faces a binary decision when it encounters an antigen: become a Th1 fighter that floods tissue with interferon-gamma (IFN-gamma) to combat intracellular pathogens, or become a Th2 helper that drives IgE and eosinophil-based responses against parasites and allergens. The master switch for the Th1 path is T-bet11 T-bet
encoded by TBX21 (T-box transcription factor 21); the transcription factor that directly activates the IFNG promoter, represses GATA3 and Th2 differentiation, and commits CD4+ T cells to the Th1 effector lineage. rs17699436 sits approximately 5 kb downstream of the TBX21 gene in the intergenic region between TBX21 and OSBPL7 on chromosome 17q21.32. It has been cited alongside TBX21-region variants in association studies of systemic autoimmune disease and is presumed to tag regulatory variation influencing the TBX21-IFNG transcriptional axis.

The Mechanism

rs17699436 maps to chr17:47,751,209 (GRCh38), positioned roughly 5 kilobases 3-prime of the TBX21 transcription end site (chr17:47,746,122). The A>G substitution lies in a region that Ensembl classifies as an intergenic variant with low evolutionary conservation (GERP score −0.48). Its functional significance is not established by direct in vitro assay, but its co-citation with TBX21 promoter and intronic variants in haplotype studies suggests it may be in linkage disequilibrium with regulatory elements that control TBX21 expression. The downstream consequence, if the G allele does tag reduced TBX21 activity, would be blunted T-bet protein output in activated CD4+ T cells — the same mechanism documented for the better-characterized rs4794067 promoter variant.

Fyall et al. (2012)22 Fyall et al. (2012) directly quantified TBX21 promoter variant effects on cytokine output in 210 healthy donors: CC carriers at rs4794067 produced significantly less IFN-gamma (p=0.02) and IL-4 (p=0.001) than TT individuals. If rs17699436 tags this same haplotype block, G-allele carriers would be expected to show a similar, if attenuated, reduction in T-bet-driven IFN-gamma production.

The Evidence

The two publications that index rs17699436 are both systemic autoimmune disease studies. Gourh et al. (2009)33 Gourh et al. (2009) studied TBX21-region variants in 902 SSc patients and 4,745 controls, finding TBX21 polymorphisms associated with altered Th1/Th2 cytokine balance: SSc patients carrying the high-risk TBX21 haplotype had elevated Th2 cytokines (IL-4, IL-5, IL-13) consistent with reduced T-bet suppression of the Th2 program. rs17699436 was cited as a TBX21-region marker in this context. Leng et al. (2016)44 Leng et al. (2016) studied the TBX21/IFNG interaction axis specifically — analyzing rs4794067 (TBX21) against rs2069705 (IFNG) in a 3,732-subject Chinese SLE cohort and found a significant gene-gene interaction: neither variant alone reached significance for SLE susceptibility, but their combination did. This finding establishes the TBX21-IFNG regulatory axis as a unit with compounded autoimmune risk potential.

The broader context for this locus in immune disease comes from studies of the TBX21 haplotype. Munthe-Kaas et al. (2008)55 Munthe-Kaas et al. (2008) identified TBX21 intronic variants associated with allergic asthma in Norwegian children with an odds ratio of 8.3 (95% CI 2.5–26.9) for homozygous risk-haplotype carriers, specifically for allergic (IgE-mediated) asthma but not non-allergic asthma. This specificity supports the mechanism: reduced T-bet activity fails to suppress Th2 responses to common allergens, leading to IgE sensitization and airway inflammation.

It is important to be transparent: the direct functional effect of rs17699436 itself has not been independently characterised. The evidence for the G allele's clinical significance is moderate — drawn from haplotype context and co-segregation with better-characterized TBX21 variants — rather than from direct functional assays or independent association studies focused exclusively on rs17699436.

Practical Implications

For G allele carriers, the primary consideration is awareness of the TBX21 regulatory axis: if this variant tags reduced T-bet activity, the practical implications mirror those of other TBX21 hypomorphic variants — a modest shift toward Th2-dominant immune responses with corresponding susceptibility to IgE-mediated allergy, reduced IFN-gamma-driven pathogen defense, and potential vulnerability to autoimmune conditions where the Th1/Th2 balance is mechanistically important. The rarity of GG homozygosity (~0.6% globally) means most carriers are AG heterozygotes, for whom the directional effect is present but attenuated relative to the better-studied CC and TT homozygote patterns at rs4794067.

Interactions

The most established interaction within this locus is between TBX21 and IFNG: T-bet directly binds the IFNG promoter and transactivates IFN-gamma gene expression. Leng et al. (2016) demonstrated that TBX21 and IFNG promoter variants interact epistatically in determining SLE susceptibility — disrupting both ends of the T-bet→IFN-gamma signal chain compounds autoimmune risk beyond either variant alone. Carriers of rs17699436 G who also carry the rs2069705 risk allele in the IFNG promoter may face additive disruption of this axis. The TBX21 haplotype containing rs11650354 and rs16947078 defines the allergic asthma risk in European children; if rs17699436 is in LD with this haplotype block, its allergy-relevant risk operates through the same Th2-permissive mechanism. The rs4794067 promoter variant is the most functionally characterized entry point into this regulatory network and should be checked alongside rs17699436 when assessing T-bet axis risk.

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal

Common genotype with typical TBX21 downstream regulatory pattern

You carry two copies of the A allele — the reference and major allele at rs17699436. About 86% of people globally carry this genotype, rising to approximately 97% in African populations. The A allele marks the common haplotype background in the TBX21/OSBPL7 intergenic region and is not associated with altered TBX21-linked immune dysregulation at this position. Your T-bet-driven Th1 immune balance is not specifically impacted by this variant.

AG Intermediate

One G allele — possible tagging of reduced TBX21-axis regulatory activity

The biological significance of the AG genotype at rs17699436 operates through the context of TBX21 haplotype structure. The intergenic G allele has been cited in studies where TBX21-region variants track with altered Th1/Th2 cytokine balance (Gourh et al. 2009, Arthritis Rheum). Functional data from related TBX21 promoter variants (Fyall et al. 2012) confirm that reduced TBX21 expression correlates with lower IFN-gamma and altered IL-4 production from stimulated T cells. The heterozygous state conveys a partial effect: one copy of the variant background allele means half of this regulatory region's contribution comes from the G-allele haplotype.

The practical implication depends on whether rs17699436 is genuinely in LD with functional TBX21 regulatory variants. Because no direct functional study has isolated rs17699436's independent effect, the evidence for action is emerging; the directional concern is plausible but not established with the same confidence as for rs4794067 or rs11650354.

GG High Risk

Rare GG homozygosity — both copies of the G allele at this TBX21-region locus

GG homozygosity at rs17699436 places both copies of this regulatory region's haplotype background on the G-allele track. In the context of TBX21's role as the master regulator of Th1 immune commitment, two copies of a variant that tags reduced TBX21 activity would predict a measurable shift toward Th2-permissive immune polarization: lower IFN-gamma output from CD4+ T cells, reduced suppression of Th2 differentiation, and potentially elevated IgE-class switching and eosinophil activity.

The limitation is that rs17699436 itself is an intergenic marker with low conservation scores, and no direct functional assay has confirmed that the GG genotype independently drives reduced TBX21 expression. The evidence level reflects this uncertainty — moderate for the TBX21 axis's biological relevance in allergic and autoimmune disease, emerging specifically for this variant's independent contribution.

Given the rarity of this genotype, GG carriers should check all TBX21-region variants together — particularly rs4794067 (promoter) and rs11650354 (intronic haplotype) — to determine whether multiple TBX21 loci compound to a high-risk haplotype profile.